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OsteopontinMutations in B3GALT6, encoding the galactosyltransferase II (GalT-II) involved in the synthesis of the gly-
cosaminoglycan (GAG) linkage region of proteoglycans (PGs), have recently been associated with a spec-
trum of connective tissue disorders, including spondyloepimetaphyseal dysplasia with joint laxity type 1
(SEMDJL1) and Ehlers–Danlos-like syndrome. Here, we report on two sisters compound heterozygous for
two novel B3GALT6 mutations that presented with severe short stature and progressive kyphoscoliosis,
joint hypermobility and laxity, hyperextensible skin, platyspondyly, short ilia, and elbow malalignment.
Microarray-based transcriptome analysis revealed the differential expression of several genes encoding
extracellular matrix (ECM) structural components, including COMP, SPP1, COL5A1, and COL15A1, enzymes
involved in GAG synthesis and in ECM remodeling, such as CSGALNACT1, CHPF, LOXL3, and STEAP4, signaling
transduction molecules of the TGFβ/BMP pathway, i.e., GDF6, GDF15, and BMPER, and transcription factors
of the HOX and LIM families implicated in skeletal and limb development. Immunoﬂuorescence analyses
conﬁrmed the down-regulated expression of some of these genes, in particular of the cartilage oligomeric
matrix protein and osteopontin, encoded by COMP and SPP1, respectively, and showed the predominant re-
duction and disassembly of the heparan sulfate speciﬁc GAGs, as well as of the PG perlecan and type III and V
collagens. The key role of GalT-II in GAG synthesis and the crucial biological functions of PGs are consistent
with the perturbation of many physiological functions that are critical for the correct architecture and ho-
meostasis of various connective tissues, including skin, bone, cartilage, tendons, and ligaments, and gener-
ates the wide phenotypic spectrum of GalT-II-deﬁcient patients.
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The major connective tissues of the body, such as skin, tendon, liga-
ments, cartilage and bone, provide the structural and informational
framework that is necessary for development. The extracellular matrix
(ECM) of connective tissues is a complex interacting network of pro-
teins, glycoproteins and proteoglycans (PGs), which provide the dy-
namic and essential environment that supports cell maintenance,
growth and differentiation. Many mutations have been identiﬁed in
the genes of either structural ECM components or enzymes involved
in their post-translational processing and folding. The molecular basis
of how thesemutations cause themyriad of connective tissue disorders
(CTDs) depends on the function of the gene product, its tissue distribu-
tion and the nature of the mutation [1,2].
PGs are the major component of the ECM in several tissues, and are
composed of core proteins and a variable number of glycosaminoglycan
(GAG) side chains that are long, unbranched polysaccharides consisting
of repeating disaccharide units of an amino sugar (N-acetylglucosamine
[GlcNAc] or N-acetylgalactosamine [GalNAc]) and a uronic acid (glucu-
ronic [GlcA] or iduronic acid [IdoA]). GAGs are distinguished in
galactosaminoglycans such as chondroitin sulfate (CS) and dermatan
sulfate (DS), and glucosaminoglycans such as hyaluronic acid (HA),
keratan sulfate, heparan sulfate (HS), and heparin (Hep) [3]. The PGFig. 1. Schematic presentation of the synthesis of the GAG backbones of CS/DS or HS chains and
its coding gene (in black) are described near the sugar symbols. After the synthesis of speciﬁc
transfers [Xyl] to the speciﬁc Ser in the endoplasmic reticulum. The synthesis of the linkage re
II, followed by the transfer of [GlcA] catalyzed by GlcAT-I in the Golgi. The ﬁrst [GalNAc] is tra
synthesis of the repeating disaccharide region of CS/DS chains. Alternatively, the addition of the
charide region of the CS/DS chain is elongated by alternate additions of [GlcA] and [GalNAc] ca
ChPF. The polymerization of the HS chain is catalyzed by HS-GlcAT-II and GlcNAcT-II activitie
and sulfation. Concerning CS chains, sulfation occurs mainly at positions 4 and 6 of [GalNAc] a
of the chondroitin backbone, [GlcA] is converted into [IdoA] resulting in the formation of the d
HS chain undergoes ﬁnal maturation, which consists of a complex series of processing reaction
O-sulfation at different positions (for an extensive review see reference [6]).superfamily is subdivided into two major groups depending on the
composition of the disaccharide building block consisting of (GalNAc-
GlcA)n or (GlcNAc-GlcA)n to form CS/DS PGs (e.g., versican, decorin)
and HS PGs (e.g., perlecan, glypican), respectively [4]. Most GAGs, ex-
cept for keratan sulfate and HA, are O-glycans that bind to the glycan
via an oxygenmolecule in the serine of the core protein [5]. GAGs exhib-
it wide-ranging structural and functional diversity as a result of their
complex biosynthetic pathway, as summarized in Fig. 1, which is a
tightly regulated process that enables the modiﬁed polysaccharide to
selectively interact with a large range of ligands [4].
The impact of the incorrect synthesis of GAGs is demonstrated by the
identiﬁcation of mutations in several genes encoding key enzymes of
this pathway, leading to severemultisystemic disorders [6] (Fig. 1). Dis-
eases caused by defects in the enzymes involved in the synthesis of the
so-called GAG linkage region, which is common to the CS/DS and HS/
(Hep) chains, are categorized as GAG linkeropathies. The ﬁrst such dis-
order to be identiﬁed was the progeroid form of Ehlers–Danlos syn-
drome (EDS), caused by mutations in B4GALT7 (GalT-I deﬁciency) [7,
8]. The characteristics of this EDS type include an aged appearance,
short stature, generalized osteopenia, hypermobile joints, hypotonic
muscles, and loose skin [9]. Recently, the recurrent p.Arg270Cys muta-
tion in B4GALT7 was demonstrated to cause “Larsen of Reunion Island
syndrome” characterized by dwarﬁsm, hyperlaxity, and multiplerelated genetic disorders. Each enzyme (glycosyltransferase and/or epimerase, in red) and
core proteins, the synthesis of the GAG-protein linkage region is initiated by XylT, which
gion is completed by the consecutive addition of two molecules of [Gal], added by GalT-I/
nsferred to the [GlcA] in the linkage region by GalNAcT-I, resulting in the initiation of the
[GlcNAc] to the linkage region by GlcNAcT-I induces HS biosynthesis. The repeating disac-
talyzed by CS-GlcAT-II and GalNAcT-II activities of a heterocomplex formed by ChSy and
s. GAG chains are ﬁnally matured by tightly controlled modiﬁcations, i.e., epimerization
nd position 2 of [GlcA] and is catalyzed by various sulfotransferases. After the formation
ermatan backbone, in which position 4 of [GalNAc] is sulfated by D4ST. The unbranched
s involving [GlcNAc] deacetylation and sulfation, epimerization of [GlcA], and subsequent
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ﬁed in a recessive Larsen-like syndrome characterized by short stature,
dysmorphic facies, joint dislocations, and cardiovascular defects [11].
Mutations in XYLT1 were identiﬁed in patients with short stature, mild
skeletal changes, and moderate intellectual disability [12]. Recently,
XYLT1 mutations were demonstrated to cause Desbuquois dysplasia
type 2 characterized by dislocations of large joints, severe pre- and
post-natal growth retardation, joint laxity, and advanced carpal ossiﬁca-
tion [13].
Downstream in the biosynthetic pathway, mutations in CHST3 are
associated with spondyloepiphyseal dysplasia Omani type, a severe
chrondrodysplasia with major involvement of the spine [14]. Further-
more, CHST3 mutations were disclosed in a number of patients who
have presented with various diagnoses, i.e., recessive Larsen syndrome,
chrondrodysplasia withmultiple dislocations, humerospinal dysostosis,
and Desbuquois syndrome [15,16]. Mutations in CHSY1 cause
Temtamy pre-axial brachydactyly syndrome [17], and defects in HS
synthesis (EXT1 and EXT2) are linked with hereditary multiple exos-
tosis types 1 and 2 [18]. Mutations in CHST14 and DSEwere reported
in musculocontractural EDS types 1 and 2, respectively [19,20], and in
adducted-thumb club foot syndrome (ATCS) [21]. Musculocontractural
EDS and ATCS patients show characteristic craniofacial features, multi-
ple congenital contractures, progressive joint and skin laxity,
kyphoscoliosis, and multisystem complications; these features overlap
with those of EDS kyphoscoliotic type, which is caused by a deﬁciency
in lysyl hydroxylase encoded by PLOD1 [22,23].
In 2013, two independent research studies identiﬁed recessive mu-
tations in B3GALT6 that constitute a novel linkeropathy (GalT-II deﬁ-
ciency) [24,25]. In particular, Nakajima et al. [24], identiﬁed B3GALT6
mutations in 7 Japanese families with spondyloepimetaphyseal dyspla-
sia with joint laxity type 1 (SEMDJL1, or SEMDJL Beighton type). In
SEMDJL1, ﬁrst described in South African patients by Beighton and
Kozlowski [26], short stature is associated with progressive spinal
malalignment, articular hypermobility especially prominent in the
hands, thoracic asymmetry, club feet, dislocation of the radial heads,
mild skin extensibility, spatulate terminal phalanges, and lip and palate
clefts. Considering the potentially lethal spinal cord compression and
pulmonary complications, survival into adulthood is reported to be un-
usual [26,27]. In other patients from 3 families with a progeroid form of
EDS, without B4GALT7 mutations, Nakajima et al. [24] performed
targeted B3GALT6 sequencing and disclosed causal mutations in all of
them, deﬁning the progeroid type 2 form of EDS. Furthermore, Malfait
et al. [25] identiﬁed B3GALT6 mutations in 3 unrelated families with a
severe recessive disease, i.e., “pleiotropic EDS-like CTD”, characterized
by severe kyphoscoliosis, joint hyperlaxity and contractures, SEMD,
skin fragility, intellectual disability, and multiple early-onset fractures.
Following the identiﬁcation of B3GALT6 as the causal gene of SEMDJL1,
Vorster et al. [28] identiﬁed B3GALT6 mutations in 8 prototype South
African families.
Here, we report 2 Moldavian sisters with clinical features reminis-
cent of the kyphoscoliotic type of EDS, or of the SEMDJL1 skeletal dys-
plasia. Genetic testing revealed compound heterozygosity for two
novel B3GALT6mutations, leading to the diagnosis of GalT-II deﬁciency.
To identify molecular mechanisms contributing to the etiopathogenesis
of GalT-II deﬁciency, transcriptome-wide expression proﬁling of skin ﬁ-
broblasts of the two sisters and immunoﬂuorescence studies were
performed.
2. Patients, materials and methods
2.1. Patients
We report on aMoldavian familywith two affected sisters, 25 and 21
years old, born from healthy non-consanguineous parents. Both pro-
bands were evaluated by clinical geneticists, and dermatologists. Writ-
ten informed consent was obtained for each proband and parentsbefore sample collection for genetic analyses. Speciﬁc consentswere ob-
tained for skin biopsy of the patients and for publication of their clinical
pictures. This study was approved by the medical ethical committee of
the University Hospital Spedali Civili of Brescia and was performed in
accordance with the Declaration of Helsinki Principles.
2.2. Cell culture and antibodies
Primary dermal ﬁbroblast cultures from both patients and from 3
sex- and age-matched healthy donors were established from skin biop-
sies by standard procedures. Fibroblasts were routinely maintained at
37 °C in a 5% CO2 atmosphere in modiﬁed Eagle's medium supplement-
ed with 10% fetal bovine serum, 100 μg/ml penicillin and streptomycin
(Life Technologies, Carlsbad, CA). Fibroblasts were expanded until full
conﬂuency was achieved and then harvested by trypsin treatment at
the same passage number. A polyclonal rabbit antibody (Ab) against
human ﬁbronectin (FN) and monoclonal antibodies (mAbs) against all
of the human isoforms of tenascin (TNs) (clone BC-24) and against CS
GAGs (clone CS-56) were from Sigma Chemicals (St. Louis, MO). The
goat anti-type I collagen (COLLI) Ab and the anti-α5β1 (clone JBS5)
and anti-α2β1 (clone BHA.2) integrin mAbs were from Millipore (Bil-
lerica, MA). The goat anti-type V collagen (COLLV) and anti-type III col-
lagen (COLLIII) Abs were from LifeSpan BioSciences, Inc. (Seattle, WA).
The rabbit anti-versican core protein Ab was from Afﬁnity Bioreagents
(Golden, CO), the rabbit anti-perlecan core protein and goat anti-
ostepontin (OPN) afﬁnity puriﬁed Abs were from Santa Cruz Biotec, Inc.
(Heidelberg, Germany), the anti-decorin (DCN) mAb (clone 115402)
was from R&D Systems, Inc. (Minneapolis, MN), and the anti-HS GAG
mAb was from USBiological Life Sciences (Swampscott, MA). The anti-
cartilage oligomeric matrix protein (COMP) RabmAb® EPR6289(2) was
from Abcam (Cambridge, UK). Rhodamine-conjugated anti-goat IgG and
anti-mouse IgM secondary Abs were from Calbiochem–Novabiochem
INTL, and the Alexa Fluor® 488 anti-rabbit and Alexa Fluor® 594 anti-
mouse secondary Abs were from Life Technologies.
2.3. Indirect immunoﬂuorescence analysis (IF)
To analyze the FN, COLLI, COLLIII, COLLV, and TNs ECM organization
and the α5β1 and α2β1 integrin distribution, ﬁbroblasts were grown,
ﬁxed and immunoreacted as previously reported [29]. The HS and CS
GAGs, perlecan, versican, and DCN organization were analyzed 48 h
from seeding by ﬁxing cells with 3% paraformaldehyde in PBS for
20 min. Subsequently, cells were incubated for 1 h with primary Abs
(anti-HS, anti-CS and anti-perlecan at 10 μg/ml; anti-DCN at 25 μg/ml;
and anti-versican diluted 1:50 in BSA 1%). The COMP and OPN distribu-
tion were analyzed by ﬁxing ﬁbroblasts in cold methanol and reacting
cells with 1.5 μg/ml anti-COMP and 4 μg/ml anti-OPN Ab, respectively.
After washing in PBS, cells were incubated for 1 h with anti-mouse or
anti-rabbit secondary Abs conjugated to Alexa Fluor® 594 and 488, re-
spectively, with the anti-goat IgG or anti-mouse IgM. The IF signals
were acquired by a CCD black-and-white TV camera (SensiCam-PCO
Computer Optics GmbH, Germany) mounted on a Zeiss ﬂuorescence-
Axiovert microscope and digitalized by Image Pro Plus software
(Media Cybernetics, Silver Spring, MD). All of the experiments were re-
peated three times.
2.4. DNA/RNA isolation and mutation analysis
Genomic DNAwas puriﬁed from blood samples of both patients and
their parents using the Wizard Genomic DNA puriﬁcation Kit (Qiagen,
Hilden, Germany) by standard procedures. Total RNA was extracted
from dermal ﬁbroblasts of both sisters and 3 unrelated controls using
the Qiagen RNeasy kit according to the manufactures' instructions
(Qiagen, Hilden, Germany). RNA quality control was assessed on an
Agilent 2100 BioAnalyzer (Agilent Technologies, Santa Clara, CA, USA).
Fig. 2. Clinical ﬁndings of the two patients. Patient 1 (a, b, g, i) and patient 2 (c–f, h, j–l) show disproportionate short stature, short trunk, severe kyphoscoliosis, generalized bone defor-
mities, genua valga, elbow contracture; dysmorphic signs: frontal bossing, blue sclerae, ﬂat oval face, broad nose (a–d); hand deformities with ﬁnger contractures and spatulate terminal
phalanges (e, f); foot deformities, i.e., ﬂat foot, hallux valgus, toe contractures (g); hyperextensible skin (h, i); marked hypermobility of small joints (j–l).
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exon boundaries, using the Primer3 tool. Primer sequences were
checked for the absence of known SNPs, based on dbSNP version 139.
In particular, all exons and intron ﬂanking regions of the PLOD1 and
B3GALT6 genes were ampliﬁed by standardized PCR. After enzymatic
cleanup of the PCR, all fragments were sequenced in both orientations
using the BigDye® Terminator Cycle Sequencing kit protocol followed
by capillary electrophoresis on an ABI3130XL Genetic Analyzer (Life
Technologies). To detect deletions/duplications, frequently observed in
the PLOD1 gene [30], MLPA analysis with the commercially available
P359-A1 probemix (MRC-Holland, Amsterdam, The Netherlands) was
also performed according to the manufacturer's recommendations.
The identiﬁed B3GALT6mutations were not found in 100 control indi-
viduals or in the 1000 Genomes Project or NHLBI Exome Variant Server
(ESP6500) databases. The mutations were annotated according to HGVS
nomenclature. To evaluate causality based on the alteration of the protein
structure, the prediction programs Align GVGD, MutationTaster,
PolyPhen-2, SIFT and KD4v in the Alamut software version 2.4were used.
2.5. Microarray hybridization and data analysis
To screen for candidate genes that may contribute to the pathogen-
esis of GalT-II deﬁciency, we performed transcriptome-wide expression
proﬁling using the Affymetrix Gene 1.0 ST platform by comparing the
gene expression patterns of skin ﬁbroblasts of the two affected sisters
with those of three healthy sex and agematched individuals. Themicro-
array analysis was performed starting from 250 ng of total RNA persample, and labeled targets were prepared using the Ambion® Whole
Transcript Expression Kit (Life Technologies) and the GeneChip® WT
Terminal Labeling and Controls Kit (Affymetrix UK Ltd, Wycombe La
High Wycombe, UK) following the manufacturers' instructions. In
brief, total RNAwas primedwith synthetic primers containing a T7 pro-
moter sequence, reverse transcribed into ﬁrst-strand cDNA and con-
verted into double-stranded cDNA. Following in vitro transcription,
10 μg of cRNA was reverse transcribed using random primers. Then,
5.5 μg of second-cycle cDNAwas fragmented, biotin labeled, andhybrid-
ized for 16 h at 45 °C onto the arrays. The chipswere thenwashed in the
Affymetrix GeneChip Fluidics station FS 450, scanned using the
Affymetrix GeneChip scanner 3000 7G system, and analyzed with the
GeneChip® Operating Software. The resulting CEL ﬁles were analyzed
using Partek® Genomics Suite software version 6.6 (Partek Inc., St.
Louis, MO), and gene-level calculation was performed using the Robust
Multichip Average algorithm. Gene expression proﬁle analysis was per-
formed using one-way ANOVA. The differentially expressed genes
(DEGs) in patients vs controls were selected based on a fold change
±2.0 and with a P-value b 0.05. Enrichment analysis of Gene Ontology
(GO), pathway analysis and functional annotation clustering were per-
formed using the PANTHER (http://www.pantherdb.org/) or DAVID
(http://david.abcc.ncifcrf.gov/) databases. To deﬁne a genotype–pheno-
type correlation of the microarray results, we intersected the list of
DEGs with the Human Phenotype Ontology (HPO) database using the
WebGestalt Toolkit (http://bioinfo.vanderbilt.edu/webgestalt/). All mi-
croarray data areMIAME compliant, and the raw data have been deposit-
ed in theMIAME compliant GEOdatabase (accession number GSE58312).
Fig. 3. Radiological ﬁndings in patient 1 (a, b, e–h) and patient 2 (c, d). a–h: severe bone loss; a, b: thoraco-lumbar kyphoscoliosis (4th degree), platyspondily, and vertebral listhesis; c, d:
dislocated and arched radial epiphysis (distal and proximal), arched radial bone, elbow malalignment, humeral overtubulation; e: hypoplastic and dislocated femoral head, femoral
overtubulation, and short ileum; f: knee malalignment; g, h: feet deformities with metacarpal shortening (astragalus hypoplasia).
5M. Ritelli et al. / Molecular Genetics and Metabolism Reports 2 (2015) 1–152.6. Quantitative real-time PCR (qPCR)
The relative mRNA levels of a series of selected genes identiﬁed by
array analysis were conﬁrmed by qPCR. Three micrograms of total RNA
puriﬁed from skin ﬁbroblasts of both patients and 3 unrelated healthy in-
dividuals were reverse-transcribed with random primers by a standard
procedure. qPCR reactionswereperformedwith SYBRGreenqPCRMaster
Mix using the ABI PRISM 7500 Real-Time PCR System by standard ther-
mal cycling conditions (Life Technologies). TheHPRT, ATP5B and CYC1 ref-
erence genes were also ampliﬁed for normalization of cDNA loading.
Relative mRNA expression levels were normalized to the geometric
mean of these housekeeping genes and analyzed using the 2−(ΔΔCt) equa-
tion. Ampliﬁcation plots, dissociation curves, and threshold cycle values
were generated by ABI Sequence detection system software version
1.3.1. Statistical analyses were performed with the GraphPad Prism soft-
ware (SanDiego, CA, USA). The resultswere expressed as themeanvaluesof relative quantiﬁcation ±SEM. Statistical signiﬁcance between groups
was determined using one-way ANOVA. P-valueswere corrected formul-
tiple testing using Tukey'smethod (*P b 0.05, **P b 0.01 and ***P b 0.001).
3. Results
3.1. Clinical ﬁndings
3.1.1. Patient 1
The 25-year-old patient was born following an uneventful pregnan-
cy and delivery. At birth, congenital bilateral hip dislocation andunspec-
iﬁed feet deformities were disclosed. At 4 years of age, the mother
reported the ﬁrst onset of severe and progressive kyphoscoliosis.
Other reported clinical data were humeral fracture after minor trauma
and episodes of dyspnea at rest. On examination at 25 years of age, we
observed the following: ﬂat and oval face, broad nose, long upper lip,
Table 1
Selection of the most up- and down-regulated DEGs identiﬁed in GalT-II-deﬁcient skin ﬁbroblasts.
Gene description Gene symbol Fold-change P-value
Up-regulated genes
STEAP family member 4 STEAP4 41.6 0.0004
Sema domain, immunoglobulin domain (Ig), short basic domain, secreted 3A SEMA3A 15.6 0.01
ATP-binding cassette, sub-family A (ABC1), member 8 ABCA8 12.5 0.03
Aquaporin 9 AQP9 10.3 0.001
Immunoglobulin superfamily, member 10 IGSF10 8.6 0.003
Tumor necrosis factor (ligand) superfamily, member 10 TNFSF10 8.6 0.007
Elav-like family member 2 CELF2 8.0 0.02
Alcohol dehydrogenase 1B (class I), beta polypeptide ADH1B 7.6 0.01
Insulin-like growth factor binding protein 2 IGFBP2 7.6 0.02
Relaxin/insulin-like family peptide receptor 1 RXFP1 6.7 0.02
Interleukin 13 receptor, alpha 2 IL13RA2 6.7 0.004
Hyaluronan synthase 2 HAS2 6.6 0.002
Cytochrome P450, family 19, subfamily A, polypeptide 1 CYP19A1 6.1 0.006
Junctional adhesion molecule 2 JAM2 6.0 0.007
Collagen and calcium binding EGF domains 1 CCBE1 5.5 0.01
Chondroitin sulfate N-acetylgalactosaminyltransferase 1 CSGALNACT1 4.7 0.01
Peroxisome proliferator-activated receptor gamma PPARG 4.5 0.003
Endothelin receptor type B EDNRB 4.4 0.001
Polypeptide N-acetylgalactosaminyltransferase 16 GALNTL1 3.4 0.04
Down-regulated genes
LIM homeobox 9 LHX9 −14.5 0.01
Tumor necrosis factor (ligand) superfamily, member 4 TNFSF4 −11.8 0.003
Oxytocin receptor OXTR −10.4 0.002
Hairy and enhancer of split 1, (Drosophila) HES1 −9.7 0.01
Cartilage oligomeric matrix protein COMP −9.1 0.004
Phosphodiesterase 1C, calmodulin-dependent PDE1C −8.9 0.004
Nuclear receptor subfamily 4, group A, member 2 NR4A2 −8.0 0.01
Potassium voltage-gated channel, KQT-like subfamily, member 5 KCNQ5 −7.9 0.02
Mohawk homeobox MKX −7.3 0.0007
Cholinergic receptor, muscarinic 2 CHRM2 −6.8 0.01
Homeobox D10 HOXD10 −6.8 0.02
Cadherin 13, H-cadherin (heart) CDH13 −4.2 0.005
Transcription factor AP-2 alpha TFAP2A −4.1 0.01
Dickkopf homologue 3 (Xenopus laevis) DKK3 −4.0 0.008
Secreted frizzled-related protein 4 SFRP4 −4.0 0.03
Lysyl oxidase-like 3 LOXL3 −3.6 0.02
Collagen, type XV, alpha 1 COL15A1 −3.6 0.005
Matrix metallopeptidase 16 (membrane-inserted) MMP16 −3.5 0.02
Short stature homeobox SHOX −3.3 0.01
Sparc/osteonectin, cwcv and kazal-like domains proteoglycan SPOCK1 −3.3 0.001
Wingless-type MMTV integration site family, member 5A WNT5A −3.3 0.03
Homeobox D11 HOXD11 −3.2 0.01
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short stature (121 cm, lower than the 3rd centile), short trunk (51 cm,
upper to lower segment ratio (U/L): 0,36, n.v. 1), thin, doughy and gener-
alized hyperextensible skin without scarring and easy bruising, toenail
dystrophy, joint hypermobility according to the Beighton score (6/9)
with recurrent dislocations, elbows contracture, severe kyphoscoliosis,
genua valga, ﬂat feet, widespread bone deformities andmuscular hypoto-
nia (Fig. 2). She requiredwalking aids. Cognitive function andophthalmo-
logic evaluation were normal.
3.1.2. Patient 2
In the 21-year-old patient, congenital bilateral hip dislocation, un-
speciﬁed feet deformities, progressive kyphoscoliosis since 7 years of
age, and episodes of dyspnea at rest were reported. On examination at
20 years of age, she presented with a clinical phenotype similar to that
of her older sister: ﬂat and oval face, broad nose, long upper lip, light
blue sclerae, yellowish teeth, disproportionate short stature (116 cm,
below the 3rd centile), short trunk (44 cm, U/L: 0,36, n.v. 1), thin,
doughy and generalized hypextensible skin without scarring and easy
bruising, toe nail dystrophy, joint hypermobility according to the
Beighton score (6/9) with recurrent dislocations, elbow contracture, se-
vere kyphoscoliosis, genua valga, ﬂat feet, widespread bone deformities
and muscular hypotonia (Fig. 2). She also required walking aids. Cogni-
tive function and ophthalmologic evaluation were normal.Total skeletal X-ray, heart ultrasound, electrocardiogram and spi-
rometrywere performed in both patients after our ﬁrst evaluation. Skel-
etal X-ray disclosed in both 4th degree thoraco-lumbar kyphoscoliosis,
generalized bone loss and spondyloepimetaphyseal deformities,
i.e., platyspondyly, vertebral listhesis, overtubulation of long bones,
dislocated and arched radial epiphysis, hypoplastic and dislocated fem-
oral head (Fig. 3). Heart ultrasound revealed mitral valve prolapse in
both sisters, and electrocardiography revealed complete right bundle
branch block in patient 1. Spirometry disclosed mild restrictive lung
disease in both patients.
These clinical ﬁndings suggested a recessive form of skeletal dyspla-
sia and, in particular, SEMDJL1, for which the genetic basis was not yet
known at the time of clinical evaluation, or a recessive form of EDS,
i.e., the kyphoscoliotic type.
3.2. Mutation analysis
Initially, mutational screening of PLOD1was performedwith a nega-
tive result. Shortly after, B3GALT6was identiﬁed as the causal gene re-
sponsible for SEMDJL1 [24], ﬁtting well with the clinical features of
our patients. Therefore, sequencing of B3GALT6 was performed in the
probands and showed compound heterozygosity for two novel muta-
tions and led to the diagnosis of GalT-II deﬁciency. In particular,
genotyping and segregation analyses revealed the maternal inherited
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ture termination codon (PTC) (p.Ile76Thrfs*202), and the paternal
c.766C N T transition, resulting in the substitution of a positively charged
arginine residue with a larger and neutral tryptophan residue in posi-
tion 256 (p.Arg256Trp) (Fig. S1). All the in silico prediction algorithms
characterized the p.Arg256Trp substitution as disease causing because
the mutated and highly conserved residue is located in the glycosyl-
transferase family 31 domain (IPR002659).
3.3. Transcriptome-wide expression proﬁling
To investigate the pathomechanisms involved in GalT-II deﬁciency,
we performed a transcriptome-wide expression analysis comparing
the gene expression patterns of the two affected patients' skin ﬁbro-
blastswith those of 3 healthy individuals. A total of 334DEGswere iden-
tiﬁed with the Partek Genomic Suite software and by applying a fold
change threshold≥±2 in combination with a P-value≤ 0.05. In partic-
ular, 172 genes were signiﬁcantly up-regulated, and 162 genes were
signiﬁcantly down-regulated. In Table 1 a selection of up- and down-
regulated transcripts, based on fold change, statistical signiﬁcance, and
possible biological relevance related to GalT-II deﬁciency, is shown
(see Table S1 for the full list of DEGs, and Fig. S2 for the scatter plot, hi-
erarchical clustering and GO analysis of the DEGs).
To identify differentially expressed pathways in GalT-II-deﬁcient
skin ﬁbroblasts compared to control cells, a pathway-enrichment anal-
ysiswas performed using the Pathway-Express algorithmenrichedwith
curated pathways of the KEGGdatabase,with a signiﬁcance threshold of
P-value b 0.05. This approach showed that the “axon guidance,” “cell ad-
hesion molecule,” “cytokine–cytokine receptor interaction,” “calcium
signaling,” “ECM–receptor interaction,” “focal adhesion,” and “TGF-
beta signaling” pathways were the most affected biological pathways
(Table 2).
To identify biological processes that are over- or under-represented
in B3GALT6-deﬁcient cells, we classiﬁed all up- and down-regulated
genes using the Functional Annotation Cluster tool available in the
DAVID database, by selecting only those terms with a P-value ≤ 0.05
and a number of genes in each annotation term ≥5. This analysis
was performed on the 172 up-regulated genes and generated 11 dis-
tinct GO clusters. As shown in Table 3 and Table S2, the GO terms
were enriched in genes with glycoprotein, leucine-rich repeat, and
immunoglobulin-like domains andwith functions necessary for chemo-
taxis, homeostatic processes, ion homeostasis, cell proliferation, migra-
tion, and morphogenesis. Interestingly, several up-regulated genes are
involved in carbohydrate and GAG binding. Functional analysis of the
162 down-regulated genes resulted in 13 different clusters. From
Table 4 and Table S3, it can been observed that the GO terms were
particularly enriched in genes with glycoprotein- and DNA-binding
domains that play a pivotal role in skeletal system and limb develop-
ment, embryonic limb and tissuemorphogenesis, and cell development.
In particular, more than a few genes in the top clusters are essential for
cell/tissue homeostasis and encode structural ECM components, such as
collagens (COLLs), glycoproteins, and PGs (COL5A1, COL15A1, COL8A1,
COMP, and SPP1), enzymes/proteins involved in post-translationalTable 2
Top canonical pathways affected in GalT-II-deﬁcient skin ﬁbroblasts.
Name P-value Ratio⁎ DE
Axon guidance 3.30E-05 10/129 EFN
Cell adhesion molecules 1.72E-04 9/34 NL
Cytokine–cytokine receptor interaction 8.04E-04 12/263 CCL
Calcium signaling pathway 0.002 9/182 GR
ECM–receptor interaction 0.009 5/84 CD
Focal adhesion 0.03 7/203 PD
TGF-beta signaling pathway 0.04 5/87 ID1
Neuroactive ligand–receptor interaction 0.04 8/256 GR
⁎ Input genes/genes in pathway, the down-regulated genes are reported in bold.processing and folding, and ECM remodeling and/or signaling (LOXL3,
MMP16, SULF1, TIMP3, LFNG, WNT5A, SFRP4, GREM2, TNFSF4, PDGFC,
CDH13, GDF6, and GDF15). Furthermore, different aspects of gene tran-
scription regulationwere affected because genes encoding transcription
factors with homeobox protein domains (DLX2, HOXA11, SHOX, MKX,
LHX9, HOXD10, and HOXD11) were the most represented.
To assess whether the differential gene expression identiﬁed in GalT-
II-deﬁcient skin ﬁbroblasts correlates with the patients' clinical features,
we intersected the list of DEGswith theHPOproject database,which is in-
tegrated in the WebGestalt Toolkit. This analysis indicated that the ob-
served perturbation of gene expression should mainly be related to the
phenotypic features that involve the skeletal system organization and
the morphology of bone structures, ﬁtting well with the clinical features
of SEMDJL1. As shown in Table 5, the HPO terms that were particularly
enriched in DEGs comprised of “abnormal morphology of the appendicu-
lar skeleton,” “abnormalities of limb bone morphology,” “abnormality of
the digits,” “abnormality of the periorbital region,” “abdominal wall de-
fect,” “aplasia/hypoplasia involving hands and bones of the upper
limbs,” and “abnormality of spinal cord.” These different classes of pheno-
typic abnormalities principally involved transcription factors, such as
HOXD10, HOXA11, SHOX, TBX3, and TFAP2A and other genes, such as
COMP, BMPER, and GDF6, all having a central role either in embryonic or
postnatal development. This consistent genotype–phenotype correlation
also increases the overall conﬁdence level of our microarray data.
To further conﬁrm the soundness of the gene expression data ob-
tained from microarray analysis, we performed qPCR and veriﬁed the
differential expression of a subset of DEGs. Genes were prioritized
based on fold change, statistical signiﬁcance, and biological relevance
related to GalT-II deﬁciency. Speciﬁcally, we focused on transcription
factors associatedwith skeletal system development, on genes associat-
edwith ECMorganization and bonemorphogenesis, and on genes relat-
ed to GAG biosynthesis and carbohydrate binding. As shown in Fig. 4a,
qPCR conﬁrmed the marked decrease of the transcriptional levels of
HOXD10, HOXD11, LHX9 and SHOX as well as the increased expression
of HOXC5 and HOXD3. Similarly, the expression levels of COMP and
SPP1 were conﬁrmed to be down-regulated. These genes encode the
cartilage oligomeric matrix protein (COMP) and osteopontin (OPN) re-
spectively, proteins that are involved in the structural integrity of the
ECM and in the bone matrix mineralization. LOXL3, which encodes an
extracellular copper-dependent amine oxidase involved in the forma-
tion of crosslinks in COLLs and elastin, was also conﬁrmed down-
regulated. The highly increased expression of STEAP4, which encodes a
member of the six-transmembrane epithelial antigen of prostate
protein family with a critical role during osteoclast differentiation, was
also validated (Fig. 4b). qPCR also showed the increase of the expression
levels of CSGALNACT1, which encodes a subunit of the GalNAcT-1 glyco-
syltransferase (Fig. 1), of GALNTL1, which encodes a member of the N-
acetylgalactosaminyltransferases (GalNAcT-16) involved in the biosyn-
thesis of mucin-type O-glycans, and HAS2, which encodes the
hyaluronan synthase 2 involved in the biosynthesis of HA. CHPF,
which encodes the chondroitin polymerizing factor (ChPf) that enters
the CS polymerase heterocomplex responsible for elongating the re-
peating disaccharide region of the CS/DS chains (Fig. 1), was conﬁrmedGs
B2, NTN1, UNC5B, EPHA2, SEMA3A, CXCL12,MET, SEMA6A, SEMA5A, PLXNA2
GN1, NCAM2, NLGN4X, CLDN11, CNTN1, HLA-DPA1, CDH2, JAM2, CD274
2, TNFRSF19, PDGFC, TNFSF10, KIT, IL1R1, CXCL6, CXCL1, CXCL12, CCL28, TNFSF4,MET
PR, ADCY4, CHRM2, AVPR1A, AGTR1, ADNRB, PLCD3, OXTR, PDE1C
47, COL5A1, SPP1, ITGA11, COMP
GFD, PDGFC, COL5A1, SPP1,MET, ITGA11, COMP
, GDF6, SMAD7, COMP, BAMBI
PR, CHRM2, GRIK2, AVPR1A, AGTR1, EDNRB, RXFP1, OXTR
Table 3
DAVID functional annotation clustering of the up-regulated genes.
Cluster Enrichment score Category Term P-value
1 7.4 SP_PIR_KEYWORDS Disulﬁde bond 2.99E-09
SP_PIR_KEYWORDS Signal 1.68E-08
SP_PIR_KEYWORDS Glycoprotein 1.81E-06
2 5.1 UP_SEQ_FEATURE Signal peptide 2.11E-08
GOTERM_CC_FAT GO:0005615—extracellular space 4.80E-05
SP_PIR_KEYWORDS Secreted 2.88E-04
3 3.1 GOTERM_CC_FAT GO:0005887—integral to plasma membrane 5.91E-05
UP_SEQ_FEATURE Topological domain:extracellular 1.78E-04
GOTERM_CC_FAT GO:0044459—plasma membrane part 2.22E-04
4 3.0 INTERPRO IPR013151:immunoglobulin 7.32E-05
SP_PIR_KEYWORDS Immunoglobulin domain 5.49E-04
INTERPRO IPR013783:immunoglobulin-like fold 0.001
5 2.5 GOTERM_BP_FAT GO:0007610—behavior 4.27E-04
INTERPRO IPR001811:small chemokine, interleukin-8-like 4.46E-04
GOTERM_BP_FAT GO:0006935—chemotaxis 7.39E-04
6 2.3 GOTERM_MF_FAT GO:0030247—polysaccharide binding 0.003
GOTERM_MF_FAT GO:0030246—carbohydrate binding 0.006
GOTERM_MF_FAT GO:0005539—glycosaminoglycan binding 0.01
7 2.2 GOTERM_BP_FAT GO:0048878—chemical homeostasis 9.66E-04
GOTERM_BP_FAT GO:0010033—response to organic substance 0.002
GOTERM_BP_FAT GO:0042592—homeostatic process 0.01
8 2.1 GOTERM_BP_FAT GO:0051270—regulation of cell motion 0.002
GOTERM_BP_FAT GO:0008283—cell proliferation 0.007
GOTERM_BP_FAT GO:0030334—regulation of cell migration 0.004
9 1.9 GOTERM_BP_FAT GO:0048878—chemical homeostasis 9.66E-04
GOTERM_BP_FAT GO:0044057—regulation of system process 0.002
GOTERM_BP_FAT GO:0050801—ion homeostasis 0.01
10 1.7 INTERPRO IPR003591:leucine-rich repeat, typical subtype 0.005
SMART SM00013:LRRNT 0.01
11 1.5 GOTERM_BP_FAT GO:0000902—cell morphogenesis 0.006
GOTERM_BP_FAT GO:0000904—cell morphogenesis involved in differentiation 0.02
GOTERM_BP_FAT GO:0006928—cell motion 0.033
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with the microarray expression data with the exception of GDF6,
which encodes a member of the bone morphogenetic protein (BMP)
family. This gene was found to be down-regulated in the microarray
analyses (Table S1), whereas qPCR showed an up-regulation.Table 4
Selection of DAVID functional annotation clusters obtained with the down-regulated genes.
Cluster Enrichment score Category
1 4.8 SP_PIR_KEYWORDS
UP_SEQ_FEATURE
GOTERM_CC_FAT
2 3.1 GOTERM_BP_FAT
GOTERM_BP_FAT
GOTERM_BP_FAT
3 2.6 UP_SEQ_FEATURE
GOTERM_CC_FAT
UP_SEQ_FEATURE
4 2.46 GOTERM_MF_FAT
GOTERM_MF_FAT
INTERPRO
5 2.45 GOTERM_BP_FAT
GOTERM_BP_FAT
GOTERM_BP_FAT
6 2.0 GOTERM_MF_FAT
GOTERM_MF_FAT
SP_PIR_KEYWORDS
7 1.98 GOTERM_BP_FAT
GOTERM_BP_FAT
GOTERM_BP_FAT
8 1.96 GOTERM_BP_FAT
GOTERM_BP_FAT
9 1.87 GOTERM_BP_FAT
GOTERM_BP_FAT
10 1.54 GOTERM_BP_FAT
GOTERM_BP_FAT
11 1.46 INTERPRO
SP_PIR_KEYWORDSAltogether, the results obtained from transcriptome-wide expres-
sion proﬁling indicate that mutations in B3GALT6 lead to the perturba-
tion of many physiological functions, from early morphogenetic
processes to postnatal development, allowing for the formation and
function of various connective tissues.Term P-value
Glycoprotein 1.35E-10
Signal peptide 3.22E-07
GO:0005576—extracellular region 2.82E-04
GO:0001501—skeletal system development 9.91E-05
GO:0060173—limb development 2.66E-04
GO:0048598—embryonic morphogenesis 0.005
Glycosylation site:N-linked (GlcNAc…) 7.53E-10
GO:0044459—plasma membrane part 0.001
Topological domain:extracellular 0.005
GO:0003700—transcription factor activity 6.84E-04
GO:0043565—sequence-speciﬁc DNA binding 0.001
IPR001356:homeobox 0.01
GO:0060284—regulation of cell development 7.11E-05
GO:0045596—negative regulation of cell differentiation 0.002
GO:0051960—regulation of nervous system development 0.006
GO:0030528—transcription regulator activity 2.91E-04
GO:0003677—DNA binding 0.04
Transcription regulation 0.03
GO:0042325—regulation of phosphorylation 0.002
GO:0043549—regulation of kinase activity 0.03
GO:0031399—regulation of protein modiﬁcation process 0.04
GO:0042981—regulation of apoptosis 0.009
GO:0043066—negative regulation of apoptosis 0.011
GO:0016481—negative regulation of transcription 0.006
GO:0016564—transcription repressor activity 0.013
GO:0030182—neuron differentiation 0.0014
GO:0048812—neuron projection morphogenesis 0.037
IPR000742:EGF-like, type 3 0.018
egf-like domain 0.025
Table 5
Summary of the HPO analysis.
HPO terms DEGs associated with phenotypic abnormalities⁎
Abnormal appendicular skeleton morphology (HP:0011844) and
abnormality of limb bone morphology (HP:0002813)
CYP19A1, SHOX, LFNG, ANKH, RIPK4, PTCH1, CBS, HOXA11, CRLF1, DSP, EGR2, PYCR1,
WNT5A, CHN1, BMPER, GDF6, CCBE1, TBX3, COL5A1, TFAP2A, EDNRB, RBPJ, SNORD116-1,
SEMA3A, KIT, COMP,MASP1, HOXD10, CNTN1
Abnormality of the digits (HP:0011297) SHOX, LFNG, RIPK4, PTCH1, CBS, HOXA11, CRLF1, DSP, EGR2,WNT5A, CHN1, BMPER,
GDF6, CCBE1, TBX3, TFAP2A, EDNRB, RBPJ, SNORD116-1, COMP,MASP1, CNTN1
Abnormality of the periorbital region (HP:0000606) BDNF, ANKH, LDLR, RIPK4, PTCH1, CDON, DSP, PYCR1,WNT5A, CHN1, BMPER, CCBE1,
AFF2, TBX3, COL5A1, TFAP2A, EDNRB, RBPJ, SNORD116-1, KIT,MASP1
Abdominal wall defect (HP:0010866) BDNF, BMPER, LFNG, CCBE1, TBX3, COL5A1, CBS, ZEB1, PTCH1,MASP1, PYCR1,WNT5A
Aplasia/hypoplasia involving hands and bones of the upper limbs
(HP:0005927, HP:0006496)
CHN1, SHOX, CCBE1, TBX3, TFAP2A, RIPK4, PTCH1, RBPJ, CRLF1, COMP,MASP1,WNT5A
Thoracoabdominal wall defects (HP:0100656) BDNF, BMPER, LFNG, CCBE1, TBX3, COL5A1, CBS, ZEB1, PTCH1,MASP1, PYCR1,WNT5A
Abnormality of spinal cord (HP:0002143) CHN1, ENPP1, BMPER, GDF6, LFNG, CCBE1, PTCH1, COMP,MASP1
Vertebral segmentation defect (HP: 0003422) PTCH1, CHN1, BMPER, GDF6, LFNG,WNT5A
⁎ Genes down-regulated in affected sisters are reported in bold.
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To investigate the pathophysiological consequences of GalT-II de-
ﬁciency on ECM architecture, the expression of the CS and HS GAGs,
the distribution of the PGs versican, perlecan, and DCN, and the orga-
nization of COLLI, COLLIII, COLLV, FN, TNs and the α2β1 and α5β1
COLLs and FN integrin receptors were investigated by IF. Further-
more, because the gene expression analysis showed a strong de-
crease of the expression levels of COMP and SPP1, the organization
of the two corresponding proteins, i.e., COMP, and OPN, was also
investigated.
As shown in Fig. 5, either COMP or OPN were expressed by control
ﬁbroblasts. In particular, COMP was distributed in the plasma mem-
brane, and large amounts of protein were stored inside the cell; OPN
was highly expressed with a perinuclear and cytoskeleton-associated
signal. In the patients' ﬁbroblasts, COMP was markedly reduced, and
OPN was quite undetectable. These protein data correlate well with
the gene expression results.
The HS GAGs were organized in a rich ﬁbrillar network covering
the control ﬁbroblasts, whereas they decreased in both patients'
cells with only a few ﬁbrils localized in the extracellular spaces and
in spots associated with the cell surface. The almost HS-speciﬁc PG
perlecan, organized by control ﬁbroblasts in a ﬁbrillar ECM meshwork
and resembling the HS GAGs distribution, was highly reduced in the
patients' ﬁbroblasts. On the other hand, the CS GAGs, investigated
using a speciﬁc Ab that does not recognize the DS GAGs, were orga-
nized with a comparable pattern in the ECM of both patients and
control cells. The CS/DS-speciﬁc PG versican was expressed by both
control and patients' cells, with a comparable cytoplasmic distribu-
tion. Similarly, the core protein of the hybrid CS/DS PG DCN was de-
tected at comparable levels in the cytoplasm and in the plasma
membrane of control and patients' cells.
Fig. 6 shows the organization in the ECM of COLLs, glycoproteins
and their speciﬁc integrin receptors in control and GalT-II-deﬁcient
cells. COLLI was mainly stored in cytoplasm and similarly organized
in thin ECM ﬁbrils in both control and patients' ﬁbroblasts. COLLIII
was assembled in the ECM by control cells, but not by GalT-II-
deﬁcient cells, in which the protein was only detected in the cyto-
plasm. COLLV ECM was organized by control and patient cells;
however, in GalT-II-deﬁcient cells, the network was reduced and dis-
organized. The ﬁbroblast-speciﬁc COLL receptor, α2β1 integrin, was
organized in thin dots on the control cell surfaces and was not re-
cruited onto the patients' cell membranes. FN and TNs were assem-
bled in ﬁbrillar ECMs in both control and patient ﬁbroblasts in a
comparable manner. Similarly, the main receptor for FN, α5β1
integrin, was distributed on both the control and patient cell plasma
membranes.4. Discussion
GalT-II deﬁciency is a recently discovered autosomal recessive con-
dition responsible for a spectrum of connective tissue disorders. In par-
ticular,mutations in B3GALT6 cause SEMDJL1, a severe skeletal dysplasia
ﬁrst documented by Beighton and Kozlowski in 1980 when the clinical
features of 7 affected children in an Afrikaans-speaking community of
South Africans were described [26]. In subsequent years, additional pa-
tients were identiﬁed, and thus far, more than 30 affected cases have
been reported in the Afrikaner population [28]. Nakajima et al. [24] de-
scribed 8 patients with SEMDJL1, all of whom had the typical skeletal
abnormalities of the disorder. Four other patients of 3 families also
had a range of extra-skeletal and connective tissue abnormalities that o-
verlapped with those observed in the progeroid form of EDS. Further-
more, Malfait et al. [25] described 5 patients with a similar phenotype
but with some substantial differences from the SEMDJL1 prototype be-
cause these patients also had soft tissue fragility with delayed wound
healing, multiple early-onset fractures and intellectual disability. In
our patients, the presence of defective growth, joint hypermobility
and modeling of the spine and long bones, the lack of tissue fragility
and intellectual disability perfectly matched with SEMDJL1. The initial
clinical suspicion of the EDS kyphoscoliotic type and the consequent
PLOD1 genetic testing were justiﬁed not only by the lack of knowledge,
at time of clinical evaluation, of the SEMDJL1 causative gene but also by
the presence of three major criteria of the EDS kyphoscoliotic type,
i.e., marked skin hyperextensibility, progressive kyphoscoliosis and
generalized joint laxity.
Altogether, in SEMDJL1, progeroid type 2 of EDS, and “pleiotropic EDS-
like CTD”, a total of 17 recessive B3GALT6mutations have been identiﬁed:
in particular, 11 (2 recurrent) mutations are missense substitutions of
highly conserved amino acids within the catalytic galactosyltransferase
domain of GalT-II with a predicted deleterious effect; 5 mutations are
small deletions leading to frameshifts and PTC formation, and they are ex-
pected to generate truncated proteins because in single-exon genes, such
asB3GALT6, nonsense-mediatedRNAdecay should not be activated, and1
mutation is a recurrent substitution in the translation initiation codon [24,
25,28, this study] (Table S4). Immunocytochemical studies of severalmu-
tant Galt-II proteins showed subcellular mislocalization, and activities of
all mutant proteins were signiﬁcantly decreased compared to wild-type
proteins, supporting loss-of-function [24,25]. The concept of differentmu-
tations in the same gene causing a spectrum of variable phenotypes is
well established in skeletal dysplasias and other disorders. An analogous
situation seems to be valid for the B3GALT6mutations, which are causa-
tive in the spectrum of the SEMDJL1 and EDS-like GAG-mediated CTDs.
Concerning the pathological mechanism of GalT-II deﬁciency some
functional studies were performed. In particular, Malfait et al. [25]
showed that B3GALT6mutations resulted in the production of immature
Fig. 4. qPCR validation of the microarray expression data. The relative mRNA expression levels of selected genes related to skeletal system development (a), ECM organization and bone
formation (b), andGAGbiosynthesis (c),were determinedwith the 2−(ΔΔCt)method normalizedwith the geometricmean of theHPRT,ATP5B and CYC1 reference genes. Bars represent the
mean ratio of target gene expression in patients' ﬁbroblasts compared to three unrelated healthy individuals. qPCRwas performed in triplicate, and the results are expressed asmeans±
SEM. In A and B, the relative mRNA levels of target genes in patients versus controls are expressed as Log10 transformed values. In C, the non-transformed relative fold change is shown.
Statistical signiﬁcance (*P b 0.05, **P b 0.01 and ***P b 0.001) was calculated with one-way ANOVA and the Tukey post hoc test.
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chains in dermal patient ﬁbroblasts. The authors also showed, by elec-
tron microscopy on a patient's skin biopsy, an abnormal collagen ﬁbril
architecture, suggesting that COLL ﬁbrillogenesis is perturbed in GalT-
II deﬁcient patients. Nakajima et al. [24], using patients' lymphoblastoid
cells, demonstrated a decrease of HS chains and a paradoxical increase
of CS/DS chains on the cell surface. The IF analysis performed on our
two patients' skin ﬁbroblasts showed a marked reduction of the HS
GAG chains ECM organization, and a complete disarray of theperlecan-ECM. Interestingly, the CS GAGs assembled into an ECM very
similar to that organized by the control cells, and the core proteins of
the hybrid CS/DS PGs DCN and versican showed a control-like distribu-
tion. Although the organization of the DS GAGs was not investigated, it
is likely that these hybrid PGs should not have a normal composition of
their CS/DS side chains, as previously shown for DCN [25].
Perlecan, encoded by HSPG2, is predominantly a HS-speciﬁc PG and
binds to several ECM components, i.e., COLLI, COLLIV, nidogen, laminin,
and FN. It has been demonstrated that the CS/HS form of perlecan, with
Fig. 5.Organization of COMP,OPN, GAGs, and PGs in SEMDJL1patients'ﬁbroblasts. Control andGalT-II-deﬁcient (patient 1: P1 andpatient 2: P2) skinﬁbroblastswere analyzedwith speciﬁc Abs
directed against COMP, OPN, HS, and CS GAGs chains, and the core proteins of the PGs perlecan, versican and DCN. Scale bar: 10 μm. Experiments were repeated three times. Representative
images are shown.
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Fig. 6.Organization of COLLs-, TNs- and FN-ECM, andα2β1 andα5β1 integrin receptors. Control and GalT-II-deﬁcient (P1 and P2) skinﬁbroblastswere analyzedwith speciﬁc Abs directed
against COLLI, COLLIII, and COLLV. TNs and FN were investigated by labeling the cells with Abs recognizing all TN and FN isoforms. The COLL- and FN-speciﬁc receptors, α2β1 and α5β1
integrins, respectively, were analyzedwith two speciﬁc mAbs recognizing their ligand-binding sites. Scale bar: 10 μm. Experiments were repeated three times. Representative images are
shown.
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COLL ECM homeostasis [31], as also shown in perlecan-null mice that
fail to form an adequate cartilage template and therefore display severe
skeletal defects [32]. Functional null mutations in HSPG2 result in lethal
forms of neonatal short-limbed dwarﬁsm, known as dyssegmental
dysplasia Silverman-Handmaker type syndrome, characterized by se-
vere cartilage matrix anomalies [33]. Schwartz–Jampel syndrome type
1 patients with hypomorphic HSPG2 mutations, display a less severe
short-stature phenotype accompanied by chondrodysplasias [34].
DCN is one of the major PGs in skin and tendon, and it was shown
that the DCN core protein is important for COLL ﬁbril formation, where-
as its CS/DS GAGs regulate the space between the COLL ﬁbrils. DCN
knockout mice have COLL ﬁbrils varying in dimension with thicker di-
ameters andwidely irregular shapes [35]. Interestingly, the biochemical
phenotype of these mutant mice overlaps with that observed in
musculocontractural EDS type/ATCS due to D4ST deﬁciency (Fig. 1). In
particular, Miyake et al. [19] analyzing ﬁbroblasts of patients with
CHST14mutations, showed that although theDCN core proteinwas nor-
mally organized, the disaccharide composition of its GAG chains
consisted only of CS, without DS chains. Therefore, a deﬁciency of
D4ST perturbs normal DS/CS balance, ﬁnally leading to disorganization
of the COLL network, underlining the pivotal role of DCN in COLL
ﬁbrillogenesis.
Altogether, the absence of HS GAG synthesis observed in our pa-
tients' ﬁbroblasts, in combination with the disorganization of perlecan
and, possibly, of other HS PGs, and the most likely abnormal CS/DS
side chain composition of hybrid PGs, such as versican, DCN and proba-
bly others, were associated with a defective COLL ﬁbril assembly, as
shown by the lack of the COLLV and COLLIII ECM and of their receptor,
the α2β1 integrin. In our patients' ﬁbroblasts, the organization into
the ECM of TNs, which are involved in the regulation of COLL
ﬁbrillogenesis, and of FN, the assembly of which is known to be depen-
dent on COLL deposition, are not affected, and the FN ﬁbril deposition is
associated with the recruitment of the FN-speciﬁc receptor, the α5β1
integrin. The FN ECM and α5β1 integrin are poorly organized in vitro
by EDS ﬁbroblasts [29,36,37], independent of the EDS type and gene
mutation, indicating that different ECM components organized by skin
ﬁbroblasts might distinguish the SEMDJL1 cellular phenotype from the
EDS phenotype.
To identify novel molecular mechanisms involved in SEMDJL1 path-
ogenesis, we performed a transcriptome wide expression proﬁling on
patients' skin ﬁbroblasts. Although the number of patients was limited
to two sisters and we are aware that the genetic variation between
them is considerably lower than between unrelated individuals, we
identiﬁed several DEGs and related pathways that should contribute
to the etiopathology of GalT-II deﬁciency, since the obtained results cor-
relate well with the pleiotropic phenotype of GalT-II-deﬁcient patients.
In particular, we identiﬁed the predominant down-regulation of nu-
merous genes with functions related to the maintenance of ECM struc-
tural integrity. For instance, COL5A1was found to be down-regulated at
either the transcriptional or translational level. COLLV plays a central
role in COLLs ﬁbrillogenesis and co-assembles with COLLI to form
heterotypic ﬁbrils. Haploinsufﬁciency of COLLV due to mutations in
COL5A1 causes classical EDS [38], characterized by widened atrophic
scars, skin hyperextensibility, and generalized joint hypermobility; the
latter two major criteria of classical EDS were also present in our
SEMDJL1 patients. Additionally, COL15A1, encoding the α1 chain of
COLLXV, was found to be down-regulated in the array. Interestingly,
COLLXV is a human osteoblast-secreted matrix protein, expressed dur-
ing osteogenic differentiation of bone marrow stromal cells in osteo-
blasts, and in bone tissue biopsies by osteoblasts forming new bone
tissue [39]. Consistent with this evidence, we can speculate that the de-
creased COL15A1 expression observed in our SEMDJL1 patients, might
be associated with an impairment of the osteogenic differentiation
and bone remodeling, likely contributing to the clinical phenotype.
Among the other down-regulated transcripts, we considered COMPand SPP1 as key genes in the context of SEMDJL1 pathogenesis and ana-
lyzed their expression at the protein level aswell. IF analyses demonstrat-
ed a reduced-to-absent organization of COMP and OPN. COMP, a non-
collagenous ECM glycoprotein expressed primarily in cartilage, ligament,
tendon, skeletal muscle and growth plate, is essential for the normal de-
velopment of cartilage and for its conversion to bone [40]. COMP binds
to COLLI, COLLII, COLLIX, COLLXII, COLLXIV, FN, and aggregan, thereby ac-
celerating ﬁbrillogenesis through the promotion ofmatrix component as-
sembly and themaintenance of the stability of the COLLs network of adult
tissues [41]. Mutations in COMP produce clinical phenotypes of
pseudoachondroplasia and multiple epiphyseal dysplasia, characterized
by disproportionate short stature, brachydactyly, joint hypermobility,
early onset osteoarthritis, and scoliosis [42]. In a recent transcriptome-
wide expression study,COMPwas found to be down-regulated in patients
with adolescent idiopathic scoliosis, and COMP was proposed as an
important biomarker in predicting scoliosis development [43].
OPN is one of themajor components ofmineralized bonematrix that
modulates the osteoblast phenotype, endochondral bone formation, the
mineralization of thematrix in physiological or pathological conditions,
wound healing and calciﬁcation [44]. It has been suggested that OPN fa-
cilitates the attachment of the osteoclasts to themineralmatrix of bones
and, consequently, promotes the osteoclastic bone resorption essential
for bone and mineral homeostasis [45].
Our ﬁndings, although obtained in vitro, indicate that B3GALT6mu-
tations, through the perturbation of the synthesis of the GAG linkage re-
gion of HS and CS/DS PGs, lead to a general dysregulation of the
deposition of structural ECM proteins, such as COLLs, OPN and COMP,
with a pivotal role for a correct ECM architecture and homeostasis of
several connective tissues.
Moreover, our analysis showed a differential expression of genes in-
volved in ECM-mediated signal transduction. In particular, the TGFβ/
BMP signaling pathway included GDF6 and BMPER, which were up-
regulated, and GDF15 which was down-regulated; these genes encode
BMPs that are known to regulate tissue differentiation andmaintenance
acting in complex signaling networks during embryonic bone forma-
tion, postnatal growth, remodeling, and regeneration of the skeleton
[46]. GDF6 is considered as a potential inhibitor of bone formation be-
cause it was shown to inhibit osteogenic differentiation of human
bone marrow stromal cells in vitro [47]. BMPER is known to inhibit
BMP2- and BMP4-dependent osteoblast differentiation and BMP-
dependent differentiation of the chondrogenic cells [48]. GDF15 has a
role in bone remodeling and is reported to be involved in human osteo-
arthritis [49]. Interestingly, a recent genome-wide analysis in a canine
model discovered GDF15 and COMP as candidate genes for congenital
hip dysplasia, a clinical feature present in both of our SEMDJL1 patients
[50]. Additionally, microarray results revealed STEAP4 as the most up-
regulated gene in GalT-II-deﬁcient ﬁbroblasts. STEAP4 is an endosomal
ferroreductase indispensable for osteoclast development and function,
since knockdown of Steap4 in bone marrow macrophages markedly
inhibited osteoclast formation by decreasing cellular iron [51]. Overall,
our data suggest that GalT-II deﬁciency leads to an imbalance in bone
remodeling caused by increased osteoclastic bone resorption and de-
creased osteoblastic bone formation.We can hypothesize that the path-
ological bone phenotype of SEMDJL1 patients, apart from the aberrant
PG synthesis, is also consequent to a reduction of osteogenic markers,
such as OPN, COLLs and COMP, in combination with an induction of os-
teogenic differentiation inhibiting factors, such asGDF6 andBMPER, and
an increased osteoclast number and/or enhanced activity likely due to
increased STEAP4 activity.
Interestingly, our microarray data also indicated the differential
expression of several enzymes involved in the synthesis and post-
translational processing of ECM components, including genes speciﬁcal-
ly implicated in GAG biosynthesis. In particular, we found an increased
CSGALNACT1 expression; this gene encodes a subunit of GalNAcT-1, a
glycosyltransferase that transfers theﬁrst GalNAc residue onto the com-
monGAG linkage region, thus initiating CS-speciﬁc biosynthesis (Fig. 1).
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HS GAG chains are not well understood. Some studies have indicated
that the amino acids of the core protein near the GAG attachment site
and the sulfation of the Gal residues in the linkage region, catalyzed
byC6ST (encoded by CHST3),may be involved in this differential assem-
bly and/or unknown additional factors, inﬂuencing the activities of the
glycosyltransferases that continue the synthesis of CS/DS or HS [6].
The enhanced CSGALNACT1 expression observed in our patients' ﬁbro-
blastsmay represent a compensatorymechanism for the perturbed syn-
thesis of the common GAG linkage region due to GalT-II deﬁciency and
could, to some extent, explain the unexpected ECM organization of the
CS GAGs by our patients' ﬁbroblasts, as shown by IF. The authentic im-
plication of GalNAcT-1 and other differentially expressed enzymes,
such as ChPf, HAS2, GalNAcT-16, LOXL3, and STEAP4, in the molecular
mechanisms involved in the etiopathogenesis of GalT-II deﬁciency,
merits future investigation.
Finally, GalT-II deﬁciency induced the altered expression of genes
encoding transcription factors, such as HOXD10, HOXD11, and SHOX,
all found signiﬁcantly down-regulated in SEMDJL1 skin ﬁbroblasts.
The majority of these genes are members of the HOX family, known
to be principally implicated in the determination of differential genetic
programs along the anterior–posterior axis of vertebrates [52]. HOXD10
is related to skeletal muscle tissue development, and its mutations
cause congenital vertical talus [53]. Hoxd11mutant mice exhibit short-
ened metacarpals and phalanges of forelimbs and hindlimbs with hypo-
plasia/aplasia of the tibiale mediale [54]. Of particular interest, the SHOX
gene encodes a transcription factor that is important for normal bone
development and is expressed in growth plate chondrocytes, where it
modulates proliferation, differentiation and cell death [55]. SHOX deﬁ-
ciency represents a common congenital form of growth failure and is
involved in the etiology of idiopathic short stature and the growth def-
icits and skeletal anomalies in Leri–Weill dyschondrosteosis, Langer
mesomelic dysplasia, and Turner syndrome [55]. In addition to short
stature, patients with SHOX deﬁciency can present a wide variety of
skeletal malformations such as shortening and bowing of the forearms,
Madelung deformity, and cubitus valgus [56]. Other down-regulated
transcription factors identiﬁed were LHX9, CRIP2, CSRP2, and TES,
which belong to the LIM homeobox family also implicated in skeletal
and limb development [57]. Altogether, these data indicate that the al-
tered gene expression of different transcription factors seems to con-
tribute to the skeletal abnormalities of SEMDJL1 patients.
In conclusion, our study revealed important gene expression chang-
es in B3GALT6 mutant ﬁbroblasts, thus providing further insights into
potential genes and molecular pathways that should contribute to the
etiopathogenesis of GalT-II deﬁciency and related multisystemic disor-
ders. The key role of GalT-II in GAG synthesis and the crucial biological
functions of PGs are consistent with the impairment ofmany physiolog-
ical processes, including embryonic and postnatal development and the
maintenance of the ECM architecture of various connective tissues,
reﬂecting the pleiotropic phenotype of GalT-II deﬁcient patients. Fur-
ther studies are needed to better delineate the involvement of some
DEGs identiﬁed in this study in the pathogenesis of GalT-II deﬁciency
and to search for therapeutic options for this severe CTD.
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